Company news
Avacta Group PLC news in 2026
Avacta Group PLC's news releases, calls and decks from 2026, newest first.
Issue of Equity
March 26, 2026
Presentations of pre|CISION® Platform Candidates
March 17, 2026
Phase 1 study opening for AVA6103
March 16, 2026
PreCISION payload delivery advantage over ADC
February 24, 2026
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
February 24, 2026
Avacta to Participate in Conference March 2026
February 18, 2026
Appointment of CSO
February 9, 2026
Avacta appoints Francis Wilson as Chief Scientific Officer
February 9, 2026
Faridoxorubicin Program Clinical Updates
February 3, 2026
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
February 3, 2026
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
January 21, 2026
FDA Clearance of IND Application for AVA6103
January 21, 2026
Year-end trading update
January 20, 2026
Avacta Announces Year-end Trading Update
January 20, 2026
Appointment of Nominated Adviser & TVR
January 20, 2026
Calls in 2026
Decks in 2026
- TD Cowen 46th Annual Healthcare Conference 2026
Conference · 14 slides · March 2026